1750 related articles for article (PubMed ID: 8631191)
1. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
2. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
3. Antiovulatory actions of RU 486: the pituitary is not the primary site of action in vivo.
Heikinheimo O; Gordon K; Lähteenmäki P; Williams RF; Hodgen GD
J Clin Endocrinol Metab; 1995 Jun; 80(6):1859-68. PubMed ID: 7775633
[TBL] [Abstract][Full Text] [Related]
4. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
5. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
6. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
7. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
9. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
10. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
11. Response to intermittent RU486 in women.
Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
[TBL] [Abstract][Full Text] [Related]
12. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
Cameron ST; Thong KJ; Baird DT
Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
[TBL] [Abstract][Full Text] [Related]
13. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
Greene KE; Kettel LM; Yen SS
Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
[TBL] [Abstract][Full Text] [Related]
14. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
Letterie GS
Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
[TBL] [Abstract][Full Text] [Related]
15. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
18. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
19. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
Niaraki MA; Moghissi KS; Borin K
Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
[TBL] [Abstract][Full Text] [Related]
20. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]